Inverness Counsel’s Idexx Laboratories IDXX Stock Holding History

Inverness Counsel’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.79M	Buy	5,503 +3,620	+192%	+$1.33M	0.1%	66
2022 Q2	$660K	Sell	1,883 -6	-0.3%	-$2.45K	0.04%	100
2022 Q1	$1.03M	Buy	1,889 +609	+48%	+$320K	0.05%	83
2021 Q4	$843K	Buy	1,280 +416	+48%	+$261K	0.03%	96
2021 Q3	$537K	Buy	864 +426	+97%	+$286K	0.02%	117
2021 Q2	$277K	Buy	+438	New	+$242K	0.01%	148
2019 Q1	–	Sell	-5,006	Closed	-$931K	–	121
2018 Q4	$931K	Sell	5,006 -44,733	-90%	-$9.17M	0.06%	73
2018 Q3	$12.4M	Buy	49,739 +14,994	+43%	+$3.64M	0.65%	39
2018 Q2	$7.57M	Buy	+34,745	New	+$7.16M	0.43%	43

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Inverness Counsel's IDXX Position: Q3 2022 in Review

Inverness Counsel increased its Idexx Laboratories (IDXX) stake by 192% in Q3 2022, buying an estimated $1.33M and bringing the position to 5,503 shares worth $1.79M. The position accounts for 0.1% of the portfolio, ranked #66.

Inverness Counsel first reported a position in IDXX in Q2 2018 and has held it in 9 quarters since. The position peaked at $12.4M in Q3 2018. 925 funds tracked by Wall St. Rank hold IDXX as of Q3 2022.

Inverness Counsel held 5,503 shares of Idexx Laboratories worth $1.79M as of Q3 2022.
Inverness Counsel bought 3,620 Idexx Laboratories shares in Q3 2022, an estimated $1.33M.
Idexx Laboratories made up 0.1% of Inverness Counsel's portfolio in Q3 2022, its #66 holding.
Inverness Counsel first reported a position in Idexx Laboratories in Q2 2018 and has held it in 9 quarters since.
Inverness Counsel's Idexx Laboratories position peaked at $12.4M in Q3 2018.
925 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.